References
72
Referenced
171
10.1016/S0165-0173(03)00174-7
/ Brain Res. Brain Res. Rev / Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta by Atwood (2003)10.1046/j.1471-4159.2000.0751219.x
/ J. Neurochem / Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1–42 by Atwood (2000)10.2174/156720510791162403
/ Curr. Alzheimer Res / Up-regulation of hypoxia-inducible factor (HIF)-1α and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30 by Avramovich-Tirosh (2010)10.2174/156720507781788927
/ Curr. Alzheimer Res / Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG by Avramovich-Tirosh (2007)10.1002/jnr.20864
/ J. Neurosci. Res / Interleukin-1α stimulates non-amyloidogenic pathway by α-secretase (ADAM-10 and ADAM-17) cleavage of APP in human astrocytic cells involving p38 MAP kinase by Bandyopadhyay (2006)10.1016/j.neurobiolaging.2004.02.022
/ Neurobiol. Aging / Secreted beta-amyloid precursor protein activates microglia via JNK and p38-MAPK by Bodles (2005)10.1016/S0166-2236(03)00067-5
/ Trends Neurosci / The metallobiology of Alzheimer's disease by Bush (2003)10.1016/j.nurt.2008.05.001
/ Neurotherapeutics / Therapeutics for Alzheimer's disease based on the metal hypothesis by Bush (2008)10.1016/j.arr.2004.01.002
/ Ageing Res. Rev / Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease by Castellani (2004)10.1002/ajh.10348
/ Am. J. Hematol / Iron chelators for the treatment of iron overload disease: Relationship between structure, redox activity, and toxicity by Chaston (2003)10.1016/S0896-6273(01)00317-8
/ Neuron / Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice by Cherny (2001)10.1074/jbc.274.33.23223
/ J. Biol. Chem / Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion by Cherny (1999)10.1074/jbc.M110.149161
/ J. Biol. Chem / Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1 by Cho (2010)10.1016/0140-6736(91)92978-B
/ Lancet / Intramuscular desferrioxamine in patients with Alzheimer's disease by Crapper McLachlan (1991)10.1007/BF00966731
/ Neurochem. Res / Effects of chelators on iron uptake and release by the brain in the rat by Crowe (1994)10.1093/jn/126.1.183
/ J. Nutr / Iron and copper interact during their uptake and deposition in the brain and other organs of developing rats exposed to dietary excess of the two metals by Crowe (1996)10.1111/j.1749-6632.2000.tb06938.x
/ Ann. N. Y. Acad. Sci / Metal chelation as a potential therapy for Alzheimer's disease by Cuajungco (2000)10.1016/j.neurobiolaging.2007.02.006
/ Neurobiol. Aging / Reversion of age-related recognition memory impairment by iron chelation in rats by De Lima (2008)10.1126/science.2111583
/ Science / Cleavage of amyloid beta peptide during constitutive processing of its precursor by Esch (1990)10.1023/A:1020799512190
/ Biometals / The copper-iron chronicles: the story of an intimate relationship by Fox (2003)10.1016/0300-483X(88)90010-8
/ Toxicology / Neurotoxicity associated with deferoxamine therapy by Freedman (1988)10.3109/10717549709051878
/ Drug Deliv / Delivery of 125I-NGF to the brain via the olfactory route by Frey (1997)10.1038/41343
/ Nature / Cloning and characterization of a mammalian proton-coupled metal-ion transporter by Gunshin (1997)10.1038/357500a0
/ Nature / Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments by Haass (1992)10.1016/j.neulet.2004.12.080
/ Neurosci. Lett / A role for hypoxia-inducible factor-1alpha in desferoxamine neuroprotection by Hamrick (2005)10.1007/s13346-011-0050-2
/ Drug Deliv. Transl. Res / Intranasal delivery of deferoxamine reduces spatial memory loss in APP/PS1 mice by Hanson (2012)10.1124/jpet.108.149807
/ J. Pharmacol. Exp. Ther / Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke by Hanson (2009)10.1126/science.1072994
/ Science / The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics by Hardy (2002)10.1126/science.1566067
/ Science / Alzheimer's disease: the amyloid cascade hypothesis by Hardy (1992)10.3233/JAD-2004-6310
/ J. Alzheimers Dis / Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease by House (2004)10.1021/bi900907a
/ Biochemistry / Ternary complexes of iron, amyloid-beta, and nitrilotriacetic acid: binding affinities, redox properties, and relevance to iron-induced oxidative stress in Alzheimer's disease by Jiang (2009)10.1083/jcb.200301115
/ J. Cell Biol / APP processing is regulated by cytoplasmic phosphorylation by Lee (2003)10.1016/j.neuroimage.2010.11.073
/ NeuroImage / Increased brain iron coincides with early plaque formation in a mouse model of Alzheimer's disease by Leskovjan (2011)10.1002/ijc.2910630421
/ Int. J. Cancer / Influence of hepatic artery occlusion and desferrioxamine on liver-tumour growth by Lindnér (1995)10.1016/S0022-510X(98)00092-6
/ J. Neurol. Sci / Copper, iron and zinc in Alzheimer's disease senile plaques by Lovell (1998)10.3233/JAD-2004-6610
/ J. Alzheimers Dis / Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3 by Lovell (2004)10.1016/S0079-6468(08)70220-0
/ Prog. J. Med. Chem / The present status of chelating agents in medicine by May (1983)10.1007/s10571-009-9401-7
/ Cell. Mol. Neurobiol / Chronic exposure to high levels of zinc or copper has little effect on brain metal homeostasis or Abeta accumulation in transgenic APP-C100 mice by Maynard (2009)10.4155/fmc.09.140
/ Future. J. Med. Chem / Mechanisms of brain iron transport: insight into neurodegeneration and CNS disorders by Mills (2010)10.1016/j.tox.2011.11.003
/ Toxicology / Deferoxamine pretreatment prevents Cr(VI)-induced nephrotoxicity and oxidant stress: Role of Cr(VI) chelation by Molina-Jijón (2012)10.1007/978-1-60327-029-8_25
/ Methods Mol. Biol / Detection and localization of markers of oxidative stress by in situ methods: application in the study of Alzheimer disease by Moreira (2010)10.1385/JMN:24:1:129
/ J. Mol. Neurosci / FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein by Morse (2004)10.1249/00005768-199305000-00006
/ Med. Sci. Sports Exer / Effects of iron supplementation and discontinuation on serum copper, zinc, calcium and magnesium levels in women by Newhouse (1993)10.2174/156720210790820172
/ Curr. Neurovasc Res / Iron leads to memory impairment that is associated with a decrease in acetylcholinesterase pathways by Perez (2010)10.1016/S0002-9343(00)00547-7
/ Am. J. Med / Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease by Praticò (2000)10.1136/jmg.2003.015552
/ J. Med. Genet / Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease by Robson (2004)10.1042/BST0361282
/ Biochem. Soc. Trans / Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: riboregulation against neural oxidative damage in Alzheimer's disease by Rogers (2008)10.2174/1389450043345272
/ Curr. Drug Targets / Metal and inflammatory targets for Alzheimer's disease by Rogers (2004)10.1074/jbc.M207435200
/ J. Biol. Chem / An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript by Rogers (2002){'key': '10.1016/j.neurobiolaging.2012.05.009_bib51', 'first-page': '209', 'article-title': "Reversal by desferrioxamine of tau protein aggregates following two days of treatment in aluminum-induced neurofibrillary degeneration in rabbit: implications for clinical trials in Alzheimer's disease", 'volume': '19', 'author': 'Savory', 'year': '1998', 'journal-title': 'Neurotoxicology'}
/ Neurotoxicology / Reversal by desferrioxamine of tau protein aggregates following two days of treatment in aluminum-induced neurofibrillary degeneration in rabbit: implications for clinical trials in Alzheimer's disease by Savory (1998)10.2174/0929867013372922
/ Curr. Med. Chem / Chemistry and biochemistry of oxidative stress in neurodegenerative disease by Sayre (2001)10.1007/s00109-006-0140-7
/ J. Mol. Med / Copper and clioquinol treatment in young APP transgenic and wild-type mice: effects on life expectancy, body weight, and metal-ion levels by Schäfer (2007)10.1016/0896-6273(91)90052-2
/ Neuron / The molecular pathology of Alzheimer's disease by Selkoe (1991)10.1016/j.neuropharm.2003.09.005
/ Neuropharmacology / Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats by Shachar (2004)10.1126/science.1439760
/ Science / Production of the Alzheimer amyloid beta protein by normal proteolytic processing by Shoji (1992)10.1046/j.1471-4159.1998.70052212.x
/ J. Neurochem / Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress by Smith (1998)10.1016/0031-9384(95)02030-6
/ Physiol. Behav / Neurobehavioral dysfunctions associated with dietary iron overload by Sobotka (1996)10.1016/j.neurobiolaging.2007.10.012
/ Neurobiol. Aging / Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid by Strozyk (2009)10.1016/j.nbd.2005.10.013
/ Neurobiol. Dis / Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer's disease by El Tannir El Tayara (2006)10.1074/jbc.M407410200
/ J. Biol. Chem / Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease by Treiber (2004)10.1080/10284150701350653
/ Nutr. Neurosci / Iron regulation in C57BLI6 and DBA/2 mice subjected to iron overload by Unger (2007)10.1196/annals.1332.003
/ Ann. N. Y. Acad. Sci / The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated region by Venti (2004)10.1006/nbdi.1999.0250
/ Neurobiol. Dis / The role of copper in neurodegenerative disease by Waggoner (1999)10.1038/416535a
/ Nature / Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo by Walsh (2002)10.1186/1750-1326-5-46
/ Mol. Neurodegener / Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model by Wang (2010)10.1016/j.spen.2006.08.008
/ Semin. Pediatr. Neurol / Iron: a new target for pharmacological intervention in neurodegenerative diseases by Whitnall (2006)10.1016/0378-4274(95)03532-X
/ Toxicol. Lett / Toxicity of iron and hydrogen peroxide: the Fenton reaction by Winterbourn (1995)10.1079/BJN19940194
/ Br. J. Nutr / Increasing intakes of iron reduce status, absorption and biliary excretion of copper in rats by Yu (1994)10.1038/nrn1537
/ Nat. Rev. Neurosci / Iron, brain ageing and neurodegenerative disorders by Zecca (2004)10.1016/j.neurobiolaging.2008.02.018
/ Neurobiol. Aging / Altered expression and distribution of zinc transporters in APP/PS1 transgenic mouse brain by Zhang (2010)10.1096/fj.09-135749
/ FASEB J / Divalent metal transporter 1 is involved in amyloid precursor protein processing and Abeta generation by Zheng (2009)10.1148/radiol.2532082324
/ Radiology / Quantitative MR phase-corrected imaging to investigate increased brain iron deposition of patients with Alzheimer disease by Zhu (2009)
Dates
Type | When |
---|---|
Created | 13 years, 2 months ago (June 19, 2012, 2:20 a.m.) |
Deposited | 1 year, 6 months ago (Jan. 25, 2024, 3:28 a.m.) |
Indexed | 4 weeks ago (July 26, 2025, 5:32 a.m.) |
Issued | 12 years, 6 months ago (Feb. 1, 2013) |
Published | 12 years, 6 months ago (Feb. 1, 2013) |
Published Print | 12 years, 6 months ago (Feb. 1, 2013) |
Funders
3
National Natural Science Foundation of China
10.13039/501100001809
Region: Asia
gov (National government)
Labels
11
- Chinese National Science Foundation
- Natural Science Foundation of China
- National Science Foundation of China
- NNSF of China
- NSF of China
- 国家自然科学基金委员会
- National Nature Science Foundation of China
- Guójiā Zìrán Kēxué Jījīn Wěiyuánhuì
- NSFC
- NNSF
- NNSFC
Awards
3
- 81000468
- 81071004
- 81100808
Program for New Century Excellent Talents in University
10.13039/501100004602
Region: Asia
gov (Local government)
Labels
3
- New Century Excellent Talents Program
- Program for New Century Excellent Talents
- NCET
Awards
1
- NCET-04-0288
Department of Education of Liaoning Province
10.13039/501100007620
Region: Asia
gov (Local government)
Labels
4
- 辽宁省教育厅
- The Educational Department of Liaoning Province
- Liaoning Provincial Education Department
- Educational Department of Liaoning Province
Awards
1
- L2010567
@article{Guo_2013, title={Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer’s disease}, volume={34}, ISSN={0197-4580}, url={http://dx.doi.org/10.1016/j.neurobiolaging.2012.05.009}, DOI={10.1016/j.neurobiolaging.2012.05.009}, number={2}, journal={Neurobiology of Aging}, publisher={Elsevier BV}, author={Guo, Chuang and Wang, Tao and Zheng, Wei and Shan, Zhong-Yan and Teng, Wei-Ping and Wang, Zhan-You}, year={2013}, month=feb, pages={562–575} }